Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Blood advances·2026

Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026

Same author

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Cancer·2026

Same author

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances·2026

Same author

Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies.

Journal of geriatric oncology·2026

Same author

Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era.

Current research in translational medicine·2026

Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026

Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026

Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026

Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026

Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026

Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 20, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Maintenance therapy in diffuse large B-cell lymphoma.

Anne-Sophie Michallet¹, Laure Lebras, Bertrand Coiffier

¹Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France. annesophie.michallet@chu-lyon.fr

Current Opinion in Oncology

|July 5, 2012

Summary

This summary is machine-generated.

Maintenance rituximab shows promise in extending response duration for diffuse large B-cell lymphoma (DLBCL). While effective with induction, its benefit after R-CHOP and in salvage therapy requires further investigation.

Related Experiment Videos

Last Updated: May 20, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Diffuse large B-cell lymphoma (DLBCL) is a significant hematologic malignancy.
Maintenance therapy aims to prolong remission and improve outcomes in DLBCL patients.

Purpose of the Study:

To review the role and efficacy of maintenance therapy in diffuse large B-cell lymphoma (DLBCL).
To evaluate the impact of rituximab as maintenance therapy in DLBCL and related lymphomas.

Main Methods:

Review of randomized phase III trials and clinical data.
Analysis of rituximab's efficacy in induction, maintenance, and salvage settings for DLBCL.

Main Results:

Maintenance rituximab improved event-free and progression-free survival in follicular lymphoma.
Rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) prolonged event-free survival, but continued use after R-CHOP showed no benefit.

Conclusions:

The role of maintenance therapy in DLBCL remains an area of investigation.
High-dose therapy with autologous stem cell transplantation is standard for relapsed DLBCL.
The utility of rituximab in salvage therapy and post-transplant maintenance for DLBCL requires further research.